Uli Bialucha
Chief Scientific Officer Xilio Therapeutics
Dr. Bialucha is a passionate life science leader with more than 15 years of experience in oncology/immuno-oncology drug discovery and preclinical development. Dr. Bialucha has served as Xilio’s chief scientific officer since August 2022 and joined Xilio as the senior vice president of research in April 2021. He joined Xilio from Immunitas Therapeutics where, as vice president of drug discovery, he led the development of a single cell genomics-based discovery platform and immuno-oncology focused therapeutic pipeline. Prior to joining Immunitas, Dr. Bialucha held roles of increasing responsibility at the Novartis Institutes for Biomedical Research, most recently leading the oncology biotherapeutics group, where he directed multiple programs towards successful entry into clinical development across a variety of modalities. Dr. Bialucha serves on the scientific advisory board for the Terri Brodeur Breast Cancer Foundation. Dr. Bialucha received his B.S. in molecular genetics from the University of Sussex and his Ph.D. in molecular cell biology from the MRC Laboratory for Molecular Cell Biology, University College London. He completed his postdoctoral training in Professor Scott Lowe’s laboratory at Cold Spring Harbor Laboratory, studying tumor suppressor gene networks using genetic mouse models of cancer.
Seminars
- Unlock the potential of masked TCEs with Xilio’s tumor-activation platform, designed to deliver potent, localised T cell activation while minimising systemic toxicities and widening the therapeutic index
- Explore next-generation ATACR bispecifics with masked CD3 domains and SEECR tri-specifics incorporating co-stimulatory signaling engineered to enhance T cell potency, persistence, and anti-tumor activity
- Gain insights into Xilio’s pipeline of wholly-owned masked TCE programs targeting PSMA, CLDN18.2, and STEAP1, advancing toward clinical translation across solid tumor indication
